-

09:33:33 PM

DAWN Stock News

DAWN - Day One Biopharmaceuticals Inc

09/11/23 8:30 AM

Nasdaq : DAWN

Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023, with 66% of patients remaining on treatment FDA filing decision expected by mid-November BRISBANE, Calif., Sept. 11, 2023

RHEA-AI

neutral

08/16/23 8:00 AM

Nasdaq : DAWN

Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience

RHEA-AI

neutral

08/07/23 4:30 PM

Nasdaq : DAWN

earnings

Day One Reports Second Quarter 2023 Financial Results and Corporate Progress

Results from FIREFLY-1 demonstrate overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated Response Assessment Neuro-Oncology High-Grade Glioma (RANO-HGG) evaluable patients presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

RHEA-AI

neutral

06/06/23 10:31 PM

Nasdaq : DAWN

offering

Day One Announces Pricing of Public Offering of Common Stock

Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the pricing of its

RHEA-AI

neutral

06/06/23 4:01 PM

Nasdaq : DAWN

offering

Day One Announces Proposed Public Offering of Common Stock

Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that it

RHEA-AI

neutral

06/04/23 12:45 PM

Nasdaq : DAWN

Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma

Overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated RANO-HGG evaluable patients The Company expects to complete rolling NDA submission in October 2023 Conference call and webcast today at 6:00 p.m. CT BRISBANE, Calif., June 04, 2023

RHEA-AI

neutral

05/30/23 8:00 AM

Nasdaq : DAWN

conferences

Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference

Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced management will

RHEA-AI

neutral

05/25/23 5:00 PM

Nasdaq : DAWN

Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage

RHEA-AI

neutral

05/01/23 9:00 AM

Nasdaq : DAWN

earnings

Day One Reports First Quarter 2023 Financial Results and Corporate Progress

FIREFLY-1 clinical abstract selected for oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Leadership team strengthened with executive appointments in clinical development and commercialization Pre-New Drug Application (NDA) meeting held April 19, 2023 with

RHEA-AI

neutral

04/26/23 9:31 AM

Nasdaq : DAWN

Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation Trial-in-progress poster from FIREFLY-2 and healthcare resource use for pediatric low-grade glioma care poster to be presented Company to host conference call and webcast on Sunday, June 4, 2023 at 6:00 PM

RHEA-AI

neutral

DAWN Data

IndustryPharmaceutical Preparation Manufacturing
Websitedayonebio.com
Security nameDay One Biopharmaceuticals Inc
SectorManufacturing
CountryUS

About Day One Biopharmaceuticals Inc

day one biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. we are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. we are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.